Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors

Conditions

• Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M)
• Nasopharyngeal Carcinoma
• Lymphoepithelial Carcinoma
• Rhabdomyosarcoma
• Neuroblastoma
• Medulloblastoma
• Wilms Tumor
• Atypical Teratoid/Rhabdoid Tumors
• Diffuse Intrinsic Pontine Gliomas
• Other EGFR-positive Pediatric Solid Tumors Deemed Eligible by the Investigator

Interventions

• DRUG: Becotatug Vedotin

Sponsor

Sun Yat-sen University